Sudarshan Pharma Q2 FY27 Consolidated Profit Rises to ₹80.88 Crore
Sudarshan Pharma reported consolidated profit after tax of ₹80.88 crore for Q2 FY27, up from ₹41.83 crore in Q2 FY26. The company completed its migration to the main board of BSE and NSE. It also plans to raise up to ₹1,500 crore via FCCBs and other securities.
The substantial increase in profit, successful stock exchange migration, and plans for significant fundraising will likely have a considerable impact on the company's valuation and investor perception.
The company reported a significant increase in consolidated profit and announced a successful migration to the main board, indicating positive operational and strategic developments.
Sudarshan Pharma Industries Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results in a meeting held on October 29, 2026, which commenced at 7:00 PM and concluded at 10:00 PM.
For the quarter ended September 30, 2026, the consolidated profit after tax stood at ₹80.88 crore. This compares to a profit of ₹41.83 crore for the same period in the previous year.
The company also reported a successful migration of its equity shares from the SME Platform of BSE Limited to the Main Board of BSE Limited and listing on the main board of the National Stock Exchange of India Limited, effective October 27, 2026.
Furthermore, Sudarshan Pharma decided to discontinue manufacturing operations at its Palghar unit to rationalize costs and focus on more profitable operations. The company also received an award from the Dubai court amounting to approximately ₹9.19 crore in a lawsuit against Regans International DMCC and others, with ₹7.49 crore already received as of September 30, 2026.
Additionally, the Board approved plans to raise funds up to ₹1,500 crore through Foreign Currency Convertible Bonds (FCCBs) and other securities. The company also completed the incorporation of a wholly-owned subsidiary, Sudarshan Industries Inc., in the USA.
What to do with a filing like this
Sudarshan Pharma Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sudarshan Pharma Industries Limited. Read the original for the full detail.